组织因子阳性膜微粒及其在肿瘤中的作用和检测

国际肿瘤学杂志››2015,Vol. 42››Issue (7): 525-528.doi:10.3760/cma.j.issn.1673-422X.2015.07.013

组织因子阳性膜微粒及其在肿瘤中的作用和检测

李会桥，张予辉

100020 首都医科大学附属北京朝阳医院呼吸科

出版日期:2015-07-08发布日期:2015-05-26
通讯作者:张予辉 E-mail:zhangyhcy@163.com
基金资助:

第47批教育部留学回国人员科研启动基金（320.6750.12623）

Roles and detection of tissue factor positive microparticle in tumor

Li Huiqiao, ZhangYuhui

Department of Respiration, Beijing Chaoyang Hospital Affiliated to Capital University of Medical Science, Beijing 100020, China

Online:2015-07-08Published:2015-05-26
Contact:ZhangYuhui E-mail:zhangyhcy@163.com

摘要/Abstract

摘要：组织因子阳性膜微粒（TFMP）通过促进肿瘤周围血管生成，进而促进肿瘤浸润和转移。目前多项研究提示TFMP与肿瘤合并血栓形成具有相关性，但相关机制尚不完全清楚。研究TFMP对肿瘤进展及血栓的预测极其重要。

李会桥，张予辉. 组织因子阳性膜微粒及其在肿瘤中的作用和检测[J]. 国际肿瘤学杂志, 2015, 42(7): 525-528.

Li Huiqiao, ZhangYuhui. Roles and detection of tissue factor positive microparticle in tumor[J]. Journal of International Oncology, 2015, 42(7): 525-528.

［1］ Castellana D, Kunzelmann C, Freyssinet JM. Pathophysiologic significance of procoagulant microvesicles in cancer disease and progression［J］. Hamostaseologie, 2009, 29(1): 51-57. ［2］ Khorana AA, Francis CW, Culakova E, et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy［J］. J Thromb Haemost, 2007, 5(3): 632-634. ［3］ Castellana D, Toti F, Freyssinet JM. Membrane microvesicles: macromessengers in cancer disease and progression［J］. Thromb Res, 2010, 125 Suppl 2: S84-88. ［4］ Hargett LA, Bauer NN. On the origin of microparticles: from "platelet dust" to mediators of intercellular communication［J］. Pulm Circ, 2013, 3(2): 329-340. ［5］ Leroyer AS, Tedgui A, Boulanger CM. Role of microparticles in atherothrombosis［J］. J Intern Med, 2008, 263(5): 528-537. ［6］ Thaler J, Ay C, Pabinger I. Clinical significance of circulating microparticles for venous thromboembolism in cancer patients［J］. Hamostaseologie, 2012, 32(2): 127-131. ［7］ Aharon A, Brenner B. Microparticles, thrombosis and cancer［J］. Best Pract Res Clin Haematol, 2009, 22(1): 61-69. ［8］ Zwicker JI, Trenor CC 3rd, Furie BC, et al. Tissue factorbearing microparticles and thrombus formation［J］. Arterioscler Thromb Vasc Biol, 2011, 31(4): 728-733. ［9］ Yu YJ, Hou XD, Li YM. Effect of tissue factor knockdown on the growth, invasion, chemoresistance and apoptosis of human gastric cancer cells［J］. Exp Ther Med, 2014, 7(5): 1376-1382. ［10］ Vignoli A, Giaccherini C, Marchetti M, et al. Tissue factor expression on platelet surface during preparation and storage of platelet concentrates［J］. Transfus Med Hemother, 2013, 40(2): 126-132. ［11］ Rauch U, Bonderman D, Bohrmann B, et al. Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor［J］. Blood, 2000, 96(1): 170-175. ［12］ Zhou L, Qi XL, Xu MX, et al. Microparticles: new light shed on the understanding of venous thromboembolism［J］. Acta Pharmacol Sin, 2014, 35(9): 1103-1110. ［13］ Zwicker JI, Liebman HA, Neuberg D, et al. Tumorderived tissue factorbearing microparticles are associated with venous thromboembolic events in malignancy［J］. Clin Cancer Res, 2009, 15(22): 6830-6840. ［14］ Zwicker JI. Predictive value of tissue factor bearing microparticles in cancer associated thrombosis［J］. Thromb Res, 2010, 125 Suppl 2: S89-91. ［15］ Voloshin T, Fremder E, Shaked Y. Small but mighty: microparticles as mediators of tumor progression［J］. Cancer Microenviron, 2014, 7(12): 11-21. ［16］ AlNedawi K, Meehan B, Micallef J, et al. Intercellular transfer of the oncogenic receptor EGFRⅧ by microvesicles derived from tumour cells ［J］. Nat Cell Biol, 2008, 10(5): 619-624. ［17］ Tesselaar ME, Romijn FP, Van Der Linden IK, et al. Microparticleassociated tissue factor activity: a link between cancer and thrombosis?［J］. J Thromb Haemost, 2007, 5(3): 520-527. ［18］ Tesselaar ME, Romijn FP, Van Der Linden IK, et al. Microparticleassociated tissue factor activity in cancer patients with and without thrombosis［J］. J Thromb Haemost, 2009, 7(8): 1421-1423. ［19］ Thomas GM, PanicotDubois L, Lacroix R, et al. Cancer cellderived microparticles bearing Pselectin glycoprotein ligand 1 accelerate thrombus formation in vivo［J］. J Exp Med, 2009, 206(9): 1913-1927. ［20］ Khorana AA, Francis CW, Menzies KE, et al. Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer［J］. J Thromb Haemost, 2008, 6(11): 1983-1985. ［21］ Manly DA, Wang J, Glover SL, et al. Increased microparticle tissue factor activity in cancer patients with venous thromboembolism［J］. Thromb Res, 2010, 125(6): 511-512. ［22］ Key NS, Chantrathammachart P, Moody PW, et al. Membrane microparticles in VTE and cancer［J］. Thromb Res, 2010, 125 Suppl 2: S80-83. ［23］ Lacroix R, Robert S, Poncelet P, et al. Overcoming limitations of microparticle measurement by flow cytometry［J］. Semin Thromb Hemost, 2010, 36(8): 807-818.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲.血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊.局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华.Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青.血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺.PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云.新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚.EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵.抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六.基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六.肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东.ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅.基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳.炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝.癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志.宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.